SCHEMBL7060255

SCHEMBL7060255

CCOC(=O)CNC(=O)N1CCN(S(=O)(=O)c2ccc(-c3ccc(F)cc3)s2)[C@@H](C(=O)NOC2CCCCO2)C1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MMP13 P45452 7/20 0.34
POLB P06746 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MMP1 P03956 4/20 0.34
MAPT P10636 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP17A1 P05093 1/20 0.33
CYP21A2 P08686 1/20 0.33
CYP11B1 P15538 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7056174 0.92 SMN1; SMN2 (0.38) ALDH1A1SMN1; SMN2MMP13MMP1MAPT
SCHEMBL7060239 0.92 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2MMP13POLBMMP1
SCHEMBL7058252 0.92 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2MMP13POLBMMP1
SCHEMBL7060656 0.92 MMP13 (0.39) ALDH1A1SMN1; SMN2MMP13POLBMMP1
SCHEMBL7055747 0.91 MMP13 (0.37) ALDH1A1SMN1; SMN2MMP13MMP1MAPT
SCHEMBL7377055 0.89 ALDH1A1 (0.38) ALDH1A1KDM4EMMP13POLBL3MBTL1
SCHEMBL7057583 0.89 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2MMP13POLBMMP1
SCHEMBL7059076 0.89 SMN1; SMN2 (0.36) ALDH1A1SMN1; SMN2MMP13POLBMMP1
SCHEMBL7053159 0.87 MMP13 (0.36) ALDH1A1SMN1; SMN2MMP13POLBMMP1
SCHEMBL7056073 0.86 SMN1; SMN2 (0.36) ALDH1A1SMN1; SMN2MMP13POLBMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030060473-A1 Piperazine compounds as inhibitors of MMP or TNF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-27 US disclosed
US-6489324-B2 TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-03 US disclosed
US-6333324-B1 FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-12-25 US disclosed
EP-0948489-A1 PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-13 EP disclosed
WO-1998027069-A1 PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060473-A1 Piperazine compounds as inhibitors of MMP or TNF MMP2, MMP1, TNF ALDH1A1 281/4885KDM4E 1604/4885SMN1; SMN2 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.